NeuroSense Therapeutics Ltd. (NRSNW) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Herzliya, Israel. The current CEO is Alon Ben-Noon.
NRSNW has 17 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $4.88M.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
